Blanket Purchase Agreement 36F79720D0075-36E79724A0020
Award Date
6/25/24
Last Date to Order
6/24/26
Federal Agency
National Acquisition Center
Awardee
Vifor (International) AG
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This federal contract IDV is a multiple award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) awarded by the U.S. Department of Veterans Affairs (VA) to the prime contractor Vifor (International) AG, a Swiss-based, foreign-owned pharmaceutical manufacturer. The contract has an ultimate completion date of November 30, 2025 and a ceiling value of $700,000. Under this IDV, Vifor (International) AG has received numerous firm-fixed price delivery orders to supply...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Vifor (International) AG. The BPA utilizes the Pharmaceuticals and Drugs GSA Schedule to provide Mircera, an anemia treatment medication, to the VA. With a potential value of $23.8 million over a base year and four option years, the BPA aims to procure Mircera to treat veterans suffering from anemia. The single award BPA has a last date to order of June 2, 2021 and was awarded on...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Recordati Rare Diseases Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The single-award BPA has a ceiling value of $3,156,115 and a period of performance from July 2021 to July 2026. The BPA is for the procurement of specialized pharmaceutical products, including Signifor, Carbaglu, Cystadane, Isturisa, and Cystadrops. These medications are used to...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) contract to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company, to provide the medication TARPEYO. This BPA, valued at $1,750,000 and running through April 2026, designates Calliditas Therapeutics US Inc. as the sole approved supplier of TARPEYO to VA medical facilities nationwide. TARPEYO is an innovative treatment for uncontrolled protein in the urine due to primary...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a specialty pharmaceutical company, a Federal Supply Schedule (FSS) contract (36F79720D0214) under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. The contract has a ceiling value of $27,736,880 and runs through August 2025. Under this multiple-award IDV, Chiesi has received several firm-fixed price delivery orders to supply the VA with 1,000mg doses of the iron chelating drug deferiprone (Ferriprox) across various VA...